## ÄorÄ'e Jevtović

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7720713/publications.pdf Version: 2024-02-01



<u>ΆορΆ'ε ΙεντονιΆ</u>τ

#	Article	IF	CITATIONS
1	The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Medicine, 2005, 6, 140-143.	2.2	138
2	Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. Aids, 2018, 32, 2405-2416.	2.2	83
3	The Frequency of Poststroke Infections and Their Impact on Early Stroke Outcome. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, 424-429.	1.6	44
4	Hepatitis C virus genotypes in Serbia and Montenegro: The prevalence and clinical significance. World Journal of Gastroenterology, 2007, 13, 355.	3.3	36
5	Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. PLoS ONE, 2014, 9, e87160.	2.5	35
6	HIV-1 Subtypes in Yugoslavia. AIDS Research and Human Retroviruses, 2002, 18, 519-522.	1.1	32
7	Nucleoside Reverse Transcriptase Inhibitor Usage and the Incidence of Peripheral Neuropathy in HIV/AIDS Patients. Antiviral Chemistry and Chemotherapy, 2003, 14, 281-284.	0.6	32
8	The dissociation between virological and immunological responses to HAART. Biomedicine and Pharmacotherapy, 2005, 59, 446-451.	5.6	30
9	The metabolic syndrome, an epidemic among HIV-infected patients on HAART. Biomedicine and Pharmacotherapy, 2009, 63, 337-342.	5.6	30
10	Herpes zoster as an immune restoration disease in AIDS patients during therapy including protease inhibitors. International Journal of STD and AIDS, 2005, 16, 475-478.	1.1	29
11	Ten Years Survey of Primary HIV-1 Resistance in Serbia: The Occurrence of Multiclass Resistance. AIDS Research and Human Retroviruses, 2014, 30, 634-641.	1.1	21
12	The role of nucleoside reverse transcriptase inhibitors usage in the incidence of hyperlactatemia and lactic acidosis in HIV/AIDS patients. Biomedicine and Pharmacotherapy, 2012, 66, 308-311.	5.6	20
13	Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy. Croatian Medical Journal, 2015, 56, 14-23.	0.7	20
14	Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 745-754.	2.9	20
15	The significance of hepatitis B virus (HBV) genotypes for the disease and treatment outcome among patients with chronic hepatitis B in Serbia. Journal of Clinical Virology, 2013, 58, 54-58.	3.1	18
16	Forensic application of phylogenetic analyses – Exploration of suspected HIV-1 transmission case. Forensic Science International: Genetics, 2017, 27, 100-105.	3.1	18
17	Oral teicoplanin for successful treatment of severe refractory Clostridium difficile infection. Journal of Infection in Developing Countries, 2015, 9, 1062-1067.	1.2	16
18	Molecular typing of the local HIV-1 epidemic in Serbia. Infection, Genetics and Evolution, 2013, 19, 378-385.	2.3	15

Äorä'e Jevtoviä‡

#	Article	IF	CITATIONS
19	Exploring Evolutionary and Transmission Dynamics of HIV Epidemic in Serbia: Bridging Socio-Demographic With Phylogenetic Approach. Frontiers in Microbiology, 2019, 10, 287.	3.5	15
20	Intravenous drug use – an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients. Archives of Medical Science, 2017, 3, 652-658.	0.9	13
21	CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. Aids, 2013, 27, 907-918.	2.2	12
22	CYP2B6 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients. Therapeutic Drug Monitoring, 2014, 36, 734-738.	2.0	10
23	Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study. BMC Infectious Diseases, 2016, 16, 106.	2.9	10
24	Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro. HIV Medicine, 2007, 8, 75-79.	2.2	9
25	Alveolar Granulocytic Sarcoma of the Mandible in a Patient with HIV. Oncology Research and Treatment, 2011, 34, 55-58.	1.2	9
26	Distribution of JC virus genotypes among serbian patients infected with HIV and in healthy donors. Journal of Medical Virology, 2014, 86, 411-418.	5.0	8
27	Higher Levels of Cystatin C in <scp>HIV</scp> / <scp>AIDS</scp> Patients with Metabolic Syndrome. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 396-401.	2.5	8
28	Lipodystrophy induced by combination antiretroviral therapy in HIV/AIDS patients: A Belgrade cohort study. Vojnosanitetski Pregled, 2014, 71, 746-750.	0.2	7
29	Treatment outcome of HAART-treated patients in a resource-limited setting: The Belgrade Cohort Study. Biomedicine and Pharmacotherapy, 2014, 68, 391-395.	5.6	6
30	Clostridium difficile infection: a Serbian single-center experience. Journal of Infection in Developing Countries, 2015, 9, 136-140.	1.2	6
31	Molecular characterization of BK virus in patients infected with human immunodeficiency virus. Medical Microbiology and Immunology, 2016, 205, 185-193.	4.8	6
32	The prognosis of patients with dissociated virological and immunological responses to HAART. Biomedicine and Pharmacotherapy, 2010, 64, 692-696.	5.6	5
33	The Importance of Haematological and Biochemical Findings in Patients with West Nile Virus Neuroinvasive Disease. Journal of Medical Biochemistry, 2016, 35, 451-457.	1.7	5
34	Lower levels of IL-4 and IL-10 influence lipodystrophy in HIV/AIDS patients under antiretroviral therapy. Experimental and Molecular Pathology, 2017, 102, 210-214.	2.1	5
35	The increasing prevalence of HIV/ <i>Helicobacter pylori</i> co-infection over time, along with the evolution of antiretroviral therapy (ART). PeerJ, 2017, 5, e3392.	2.0	5
36	Uptake of Tenofovir-Based Antiretroviral Therapy among HIV–HBV-Coinfected Patients in the EuroSIDA Study. Antiviral Therapy, 2018, 23, 405-413.	1.0	5

Äorä'e Jevtoviä‡

#	Article	IF	CITATIONS
37	Influence of <i>SLCO1B1</i> polymorphisms on lopinavir <i>C</i> <sub>trough</sub> in Serbian HIV/AIDS patients. British Journal of Clinical Pharmacology, 2020, 86, 1289-1295.	2.4	5
38	Correlation between metabolic syndrome and relative telomere length shortening in HIV/AIDS patients on combined antiretroviral therapy. Experimental Gerontology, 2021, 147, 111269.	2.8	5
39	The Prognosis of Late Presenters in the Era of Highly Active Antiretroviral Therapy in Serbia. The Open Virology Journal, 2009, 3, 84-88.	1.8	5
40	Risk for toxoplasmic encephalitis in AIDS patients in Yugoslavia. International Journal of Infectious Diseases, 1997, 2, 74-78.	3.3	4
41	The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART. Biomedicine and Pharmacotherapy, 2008, 62, 21-25.	5.6	4
42	Non-specific inflammatory parameters in patients with pandemic H1N1 influenza. Biomedicine and Pharmacotherapy, 2013, 67, 218-220.	5.6	4
43	Correlation of Leptin, Adiponectin, and Resistin Levels in Different Types of Lipodystrophy in HIV/AIDS Patients. Metabolic Syndrome and Related Disorders, 2017, 15, 153-159.	1.3	4
44	Analysis of variability of urinary excreted JC virus strains in patients infected with HIV and healthy donors. Journal of NeuroVirology, 2018, 24, 305-313.	2.1	4
45	Severe hepatotoxicity induced by efavirenz in a treatment-naĀ <sup>-</sup> ve, low body mass index HIV-infected, female patient with no hepatitis and other virus co-infections. Ultrastructural Pathology, 2019, 43, 220-223.	0.9	4
46	Ageing with HIV - a periodontal perspective. New Microbiologica, 2018, 41, 61-66.	0.1	4
47	CMV DNA in blood and CSF of HIV infected patients. Virus Research, 2002, 85, 117-122.	2.2	3
48	The prognosis of CMV retinitis among patients with AIDS in Serbia. Biomedicine and Pharmacotherapy, 2008, 62, 443-447.	5.6	3
49	The Prognosis of Pediatric AIDS in Serbia. Current HIV Research, 2009, 7, 287-292.	0.5	3
50	Clinical and Immunologic Outcomes of HAART-Treated HIV-Infected Women in Resource Constrain Settings: The Belgrade Study. Women and Health, 2014, 54, 35-47.	1.0	3
51	Rubella immune status of neonates – a window towards seroprevalence among childbearing women. BMC Public Health, 2016, 16, 838.	2.9	3
52	Helicobacter pylori infection rates in dyspeptic Serbian HIV-infected patients compared to HIV-negative controls. PLoS ONE, 2021, 16, e0248041.	2.5	3
53	Correlation between PAI-1, leptin and ferritin with HOMA in HIV/AIDS patients. Experimental and Molecular Pathology, 2018, 105, 115-119.	2.1	2
54	The treatment outcome of chronic HBV infection among HBV/HIV co-infected and HBV mono-infected patients. International Journal of STD and AIDS, 2020, 31, 38-45.	1.1	2

Äorä'e Jevtoviä‡

#	Article	IF	CITATIONS
55	Predicting HIV treatment response in Romania – Comment. Germs, 2012, 2, 23-24.	1.3	2
56	Highlights from the 13th European AIDS Conference (EACS). Germs, 2012, 1, 9-11.	1.3	2
57	Herpes simplex virus resistance to acyclovir in routine virological laboratory practice. Biomedicine and Pharmacotherapy, 2005, 59, 135-136.	5.6	1
58	HIV/AIDS mortality in a south east European country versus a west European country. Journal of the International AIDS Society, 2014, 17, 19620.	3.0	1
59	Nosocomial infections in the Intesive care unit, University hospital for infectious and tropical diseases, Belgrade, Serbia. Vojnosanitetski Pregled, 2014, 71, 131-136.	0.2	1
60	Influenza A H1N1 virus infection among pregnant women in a tertiary hospital in Belgrade, Serbia. Journal of Infection in Developing Countries, 2018, 12, 380-384.	1.2	1
61	Serbian lymphoma study group (SLG): The prognosis of AIDS-related non-Hodgkin's lymphoma. Biomedicine and Pharmacotherapy, 2008, 62, 12-15.	5.6	0
62	High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia. Intervirology, 2017, 60, 43-47.	2.8	0
63	Association of tuberculosis and tricuspid valve endocarditis in AIDS patient with Ebstein heart anomaly. Journal of Infection in Developing Countries, 2018, 11, 967-970.	1.2	0
64	Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia. Journal of Virus Eradication, 2016, 2, 32-5.	0.5	0